Research & Clinical Trials
Explore our therapeutic research areas and ongoing clinical trials advancing next-generation treatments across critical medical domains.
Therapeutic Areas
Oncology
Our oncology research program focuses on developing novel targeted therapies and immunotherapeutic approaches for solid tumors and hematological malignancies. Through precision medicine and advanced biomarker-driven trial designs, we aim to improve patient outcomes across a wide range of cancer types.
Immunology
Our immunology division investigates the complex mechanisms of immune response to develop breakthrough treatments for autoimmune disorders, allergic diseases, and immune deficiencies. We leverage cutting-edge monoclonal antibody technology and immune checkpoint modulation.
Neuroscience
MedHubs neuroscience research addresses critical unmet needs in neurological and psychiatric disorders. Our pipeline includes novel treatments for neurodegenerative diseases, mood disorders, and chronic pain through innovative mechanisms of action.
Infectious Diseases
Our infectious disease research combats emerging pathogens and antibiotic-resistant bacteria through next-generation antivirals, novel antibiotics, and vaccine platforms. We maintain rapid response capabilities for pandemic preparedness and global health security.
Rare Diseases
The rare diseases program at MedHubs is dedicated to developing transformative therapies for patients with genetic and orphan diseases. Using gene therapy, enzyme replacement, and RNA-based approaches, we bring hope to underserved patient populations.
AI-Driven Drug Discovery
Our AI-driven drug discovery platform combines machine learning, molecular simulations, and vast chemical libraries to accelerate the identification and optimization of novel drug candidates. This approach significantly reduces development timelines and improves success rates.
Clinical Trials
MH-AI-501: AI-Designed Kinase Inhibitor in Solid Tumors
A Phase I dose-finding study of a first-in-class kinase inhibitor identified through AI-driven molecular screening. This trial evaluates safety, tolerability, and recommended Phase II dose in patients with advanced solid tumors.
MH-RARE-101: Gene Therapy for Spinal Muscular Atrophy Type II
A single-arm, open-label Phase I/II study to evaluate the safety and preliminary efficacy of an AAV9-based gene therapy vector in pediatric patients with Spinal Muscular Atrophy Type II.
MH-INF-402: Phase II Broad-Spectrum Antiviral for Respiratory Viruses
A randomized, placebo-controlled Phase II study evaluating the efficacy and safety of a novel broad-spectrum antiviral agent for the treatment of acute respiratory viral infections including influenza and RSV.
MH-NEURO-104: Phase I/II Study of BDNF Mimetic in Early-Stage Alzheimer's Disease
A first-in-human, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of a novel BDNF mimetic compound in patients with early-stage Alzheimer's disease and confirmed amyloid pathology.
MH-IMM-205: Phase II Evaluation of Novel Anti-IL-17 Antibody in Psoriatic Arthritis
An open-label, multi-center Phase II study assessing the efficacy, safety, and pharmacokinetics of a novel anti-IL-17 monoclonal antibody in patients with moderate-to-severe psoriatic arthritis who have inadequate response to conventional DMARDs.
MH-ONC-301: Phase III Study of MedHubs Targeted Therapy in Advanced Non-Small Cell Lung Cancer
A randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy and safety of MH-ONC-301 in combination with standard chemotherapy for patients with advanced NSCLC harboring specific molecular alterations.
MH-AI-501: AI-Designed Kinase Inhibitor in Solid Tumors
A Phase I dose-finding study of a first-in-class kinase inhibitor identified through AI-driven molecular screening. This trial evaluates safety, tolerability, and recommended Phase II dose in patients with advanced solid tumors.
MH-RARE-101: Gene Therapy for Spinal Muscular Atrophy Type II
A single-arm, open-label Phase I/II study to evaluate the safety and preliminary efficacy of an AAV9-based gene therapy vector in pediatric patients with Spinal Muscular Atrophy Type II.
MH-INF-402: Phase II Broad-Spectrum Antiviral for Respiratory Viruses
A randomized, placebo-controlled Phase II study evaluating the efficacy and safety of a novel broad-spectrum antiviral agent for the treatment of acute respiratory viral infections including influenza and RSV.
MH-NEURO-104: Phase I/II Study of BDNF Mimetic in Early-Stage Alzheimer's Disease
A first-in-human, dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of a novel BDNF mimetic compound in patients with early-stage Alzheimer's disease and confirmed amyloid pathology.
MH-IMM-205: Phase II Evaluation of Novel Anti-IL-17 Antibody in Psoriatic Arthritis
An open-label, multi-center Phase II study assessing the efficacy, safety, and pharmacokinetics of a novel anti-IL-17 monoclonal antibody in patients with moderate-to-severe psoriatic arthritis who have inadequate response to conventional DMARDs.
MH-ONC-301: Phase III Study of MedHubs Targeted Therapy in Advanced Non-Small Cell Lung Cancer
A randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy and safety of MH-ONC-301 in combination with standard chemotherapy for patients with advanced NSCLC harboring specific molecular alterations.